Skip to main content
. 2017 Jun 30;23(3):230–238. doi: 10.3350/cmh.2017.0003

Figure 2.

Figure 2.

Cumulative rates of VR according to TDF rescue therapy. The rates of VR among the three groups (TDF monotherapy, TDF+LAM, and TDF+ETV) were not statistically significant at 12 months (59.3%, 78.9%, and 51.8%, respectively) or at 24 months (88.4%, 94.7%, and 84.2%). VR, virologic response; TDF, tenofovir disoproxil fumarate; ETV, entecavir; LAM, lamivudine.